Healthcare services company The Ensign Group (NASDAQ: ENSG) fell short of the market’s revenue expectations in Q3 2026, but sales rose 14.5% year on year to $1.48 billion. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $5.91 billion at the midpoint. Its GAAP profit of $1.76 per share was 2.8% below analysts’ consensus estimates.
Is now the time to buy ENSG? Find out in our full research report (it’s free for active Edge members).
The Ensign Group (ENSG) Q3 2026 highlights:
- Revenue $1.48 billion vs S&P analysts’ estimates of $1.60 billion (14.5% year-on-year growth, 7.1% miss)
- EPS (GAAP) $1.76 vs analyst expectations of $1.81 (2.8% miss)
- Adjusted EBITDA $190.7 million vs analyst estimates of $186.2 million (12.9% margin, 2.4% beat)
- Revenue guidance The company slightly lifted its revenue guidance for the full year to $5.91 billion at the midpoint from $5.90 billion
- GAAP EPS guidance $7.98 at the midpoint for the full year, beating analyst estimates by 12.6%
- Operating margin 9.3%, up from 7.4% in the same quarter last year
- Sales volumes rose 13.1% year on year (15.1% in the same quarter last year)
- Market capitalization $10.65 billion
StockStory’s take
The Ensign Group’s third quarter drew a positive market reaction despite missing Wall Street’s revenue and earnings per share expectations, as investors looked beyond headline numbers to underlying business momentum. Management attributed the quarter’s performance to continued gains in occupancy and skilled mix, with CEO Barry Port highlighting a “relentless patient-focused culture” and ongoing success in integrating new operations. The company’s clinical outcomes, validated by above-average quality ratings and lower staff turnover, played a significant role in attracting more complex cases and expanding relationships with managed care partners.
Looking forward, the company’s updated full-year guidance is shaped by confidence in its ability to maintain strong occupancy, leverage recent acquisitions, and continue operational improvements. Management plans to accelerate organic growth by further expanding its integrated care model and investing in efficiency initiatives, particularly in clinical documentation and decision support. CFO Suzanne Snapper emphasized that guidance reflects both the contribution of recently acquired facilities and expectations for steady reimbursement rates, while CEO Barry Port noted, “We fully expect our local teams to continue executing, innovating, and integrating new operations while delivering strong results.”
Key insights from management’s remarks
Management linked third quarter momentum to operational execution, expansion into new markets, and a differentiated clinical approach that has supported both organic and acquisition-led growth.
- Integrated clinical model: The company’s “1 CLINICAL” approach, which closely coordinates therapy and nursing, was identified as a key factor in improving patient outcomes and supporting higher skilled mix. Management sees this as a compounding competitive advantage, helping to win trust from hospitals and managed care organizations.
- Occupancy and skilled mix gains: Third quarter occupancy rates and skilled mix revenue both increased year over year, with same-store facilities reporting higher Medicare and managed care volumes. Management credits these gains to strong local leadership and consistent delivery of superior clinical outcomes, which in turn drive referrals and resident choice.
- Expansion into new markets: The acquisition of 22 new operations, including a first-time entry into Florida, was a major emphasis. Management described Florida as a “dynamic healthcare market” with significant long-term upside, though also noted unique challenges such as a busy litigation environment and the need to prove clinical performance to local payers.
- Leadership development and retention: The company highlighted improved employee and administrator stability, with a lower turnover rate than industry peers. This leadership continuity enables smoother integration of new acquisitions and supports ongoing quality improvement.
- Real estate strategy and capital flexibility: The company continued to acquire both operating assets and real estate, with Standard Bear Healthcare REIT expanding its portfolio. Management noted that owning more real estate assets provides operational flexibility and additional upside, while a strong balance sheet and available credit enable continued acquisition activity.
Drivers of future performance
Ensign’s outlook is underpinned by further organic occupancy growth, performance from recent acquisitions, and margin improvement initiatives.
- Organic occupancy improvement: Management expects to drive higher occupancy and skilled mix across the portfolio by replicating best practices seen in top-performing facilities. Continued investment in clinical programs is expected to attract more complex cases and support market share gains.
- Integration of new acquisitions: The company plans to focus on turning around recently acquired operations, particularly in Florida and Texas. Management cautioned that these acquisitions are “very challenged” and will take time to contribute meaningfully to financial results, but sees long-term upside as local teams implement Ensign’s clinical and operational playbook.
- Technology and efficiency investments: Ensign is accelerating adoption of technology to improve administrative efficiency and clinical documentation. Projects in partnership with electronic medical record (EMR) providers, as well as internally developed tools, aim to support clinicians in real-time decision making and enhance compliance, with management expecting these efforts to drive margin expansion over time.
Catalysts in upcoming quarters
Looking ahead, the StockStory team will focus on (1) the pace of occupancy and skilled mix improvement in both legacy and newly acquired facilities, (2) evidence that operational and clinical integration is yielding margin and revenue gains, particularly in challenging markets like Florida and Texas, and (3) the rollout and impact of technology-driven efficiency initiatives. Continued discipline in acquisitions and leadership development will also be key drivers of future performance.
The Ensign Group currently trades at $188.25, up from $169.50 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).
Now could be the perfect time to invest in these stocks
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
